Literature DB >> 32082838

A case of rivaroxaban associated spontaneous hemothorax.

İbrahim Yıldız1, Ebubekir Aksu2, Pınar Özmen Özmen Yıldız1, İsmail Gürbak1.   

Abstract

New oral anticoagulants have emerged as an alternative for warfarin for thromboembolic prevention in patients with nonvalvular atrial fibrillation. Although new oral anticoagulants have better compliance and safety margin compared to warfarin, we must be cautious with their usage. In this article, we report a case of spontaneous hemothorax related to rivaroxaban treatment. According to our research, this is the first case of spontaneous hemothorax secondary to rivaroxaban treatment.
Copyright © 2019, Turkish League Against Rheumatism.

Entities:  

Keywords:  Hemorrhage; rivaroxaban; spontaneous hemothorax

Year:  2019        PMID： 32082838      PMCID： PMC7021367          DOI： 10.5606/tgkdc.dergisi.2019.15090

Source DB:  PubMed          Journal:  Turk Gogus Kalp Damar Cerrahisi Derg        ISSN： 1301-5680            Impact factor:   0.332


  10 in total

1.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

2.  Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.

Authors:  Dagmar Kubitza; Michael Becka; Wolfgang Mueck; Atef Halabi; Haidar Maatouk; Norbert Klause; Volkmar Lufft; Dominic D Wand; Thomas Philipp; Heike Bruck
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

Review 3.  Spontaneous hemothorax: a comprehensive review.

Authors:  Hakim Azfar Ali; Michael Lippmann; Uday Mundathaje; Ghulam Khaleeq
Journal:  Chest       Date:  2008-11       Impact factor: 9.410

Review 4.  Etiology and management of spontaneous haemothorax.

Authors:  Davide Patrini; Nikolaos Panagiotopoulos; Jonathan Pararajasingham; Lasha Gvinianidze; Yassir Iqbal; David R Lawrence
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

5.  [A rare complication of oral anticoagulant treatment: hemothorax].

Authors:  Aydın Çiledağ; Gökhan Çelik; Gözde Köycü; Eren Gürsoy; Cabir Yüksel
Journal:  Tuberk Toraks       Date:  2012

6.  [Hemothorax with high number of eosinophils following warfarin overdose].

Authors:  Jacek Nasiłowski; Rafał Krenke
Journal:  Pneumonol Alergol Pol       Date:  2002

Review 7.  Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Authors:  Jochen Graff; Sebastian Harder
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

8.  Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.

Authors:  Tuukka A Helin; Anja Pakkanen; Riitta Lassila; Lotta Joutsi-Korhonen
Journal:  Clin Chem       Date:  2013-02-01       Impact factor: 8.327

Review 9.  Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.

Authors:  Elizabeth Brem; Alex Koyfman; Mark Foran
Journal:  J Emerg Med       Date:  2013-01-30       Impact factor: 1.484

10.  Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.

Authors:  W Mueck; M Becka; D Kubitza; B Voith; M Zuehlsdorf
Journal:  Int J Clin Pharmacol Ther       Date:  2007-06       Impact factor: 1.366
  10 in total
  1 in total

1.  Sudden hemothorax as a rare initial manifestation of bronchiectasis under a direct oral anticoagulant.

Authors:  Hikaru Nakayama; Asuka Uebayashi; Shota Yagi; Shuhei Iizuka; Yoshiro Otsuki; Toru Nakamura
Journal:  Surg Case Rep       Date:  2022-09-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.